{"name":"New Mexico Cancer Research Alliance","slug":"new-mexico-cancer-research-alliance","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Mellaril","genericName":"Mellaril","slug":"mellaril","indication":"Other","status":"discontinued"},{"name":"Aprepitant vs. Gabapentin","genericName":"Aprepitant vs. Gabapentin","slug":"aprepitant-vs-gabapentin","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)","status":"phase_2"},{"name":"Erlotinib PO and Vidaza IV","genericName":"Erlotinib PO and Vidaza IV","slug":"erlotinib-po-and-vidaza-iv","indication":"Other","status":"phase_1"},{"name":"Hydralazine and Valproic Acid: Cohort -1","genericName":"Hydralazine and Valproic Acid: Cohort -1","slug":"hydralazine-and-valproic-acid-cohort-1","indication":"Other","status":"phase_1"},{"name":"raltegravir and cisplatin","genericName":"raltegravir and cisplatin","slug":"raltegravir-and-cisplatin","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Gemcitabine and Oxaliplatin","genericName":"Gemcitabine and Oxaliplatin","slug":"gemcitabine-and-oxaliplatin","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Gleevec and Arsenic Trioxide","genericName":"Gleevec and Arsenic Trioxide","slug":"gleevec-and-arsenic-trioxide","indication":"Chronic myeloid leukemia","status":"phase_2"}]}],"pipeline":[{"name":"Gemcitabine and Oxaliplatin","genericName":"Gemcitabine and Oxaliplatin","slug":"gemcitabine-and-oxaliplatin","phase":"phase_3","mechanism":"Gemcitabine and oxaliplatin work together as a chemotherapy combination to damage cancer cell DNA and prevent cell division through complementary mechanisms.","indications":["Pancreatic cancer","Colorectal cancer","Biliary tract cancer","Gastric cancer"],"catalyst":""},{"name":"Gleevec and Arsenic Trioxide","genericName":"Gleevec and Arsenic Trioxide","slug":"gleevec-and-arsenic-trioxide","phase":"phase_2","mechanism":"Tyrosine kinase inhibitor","indications":["Chronic myeloid leukemia","Acute promyelocytic leukemia"],"catalyst":""},{"name":"Mellaril","genericName":"Mellaril","slug":"mellaril","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aprepitant vs. Gabapentin","genericName":"Aprepitant vs. Gabapentin","slug":"aprepitant-vs-gabapentin","phase":"phase_2","mechanism":"Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist, which blocks the action of substance P, a natural substance in the body that causes nausea and vomiting.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)","Postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"Erlotinib PO and Vidaza IV","genericName":"Erlotinib PO and Vidaza IV","slug":"erlotinib-po-and-vidaza-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hydralazine and Valproic Acid: Cohort -1","genericName":"Hydralazine and Valproic Acid: Cohort -1","slug":"hydralazine-and-valproic-acid-cohort-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"raltegravir and cisplatin","genericName":"raltegravir and cisplatin","slug":"raltegravir-and-cisplatin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE41SXMyamZoZEZRcnFtRFdyR3ZFZkVWN3g1VzZidUdjZjljNDd6bmtLUVpRLUlfV2s4ajZNNmFLY0NpTDZzVnlwY3FhUmh3Nld2bXlJVVk2cWh4U3ZxS29N?oc=5","date":"2026-01-16","type":"regulatory","source":"Nature","summary":"Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial - Nature","headline":"Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1JZGpsWl9xZ2RrM1VXUXd2V01zMi1STDlfS0ViM0NRelFyYmJSYjdKWVpjdERTU0tMRlhGaVFiS1ZRMWRsT185cmdvWnZmMnczLVliU3huU0tPNmRnRnl6VnY2NmtGNFZFWDZGbXZ4eWNtQThCdGc?oc=5","date":"2025-05-31","type":"pipeline","source":"The American Journal of Managed Care® (AJMC®)","summary":"Community Oncology Bracing for IRA Impact - The American Journal of Managed Care® (AJMC®)","headline":"Community Oncology Bracing for IRA Impact - The American Journal of Managed Care® (AJMC®)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPbHpuNjJUZ2FUUm5POHFhb0E2a2VVS29JMVU1TThrMC1yMktpb3NxRS0yNDBpZnR1dm53R3pJRDZ3blBsbjliaUZGR0RnbGhaTDExcmFvZTQ2bXpaYXhpTmNkQXRkeXNTVDBnQVE1eWN6NHA5azZtWUk2Vk12Y2t1eEE3REpYTVhqNHdwV292TzNBdk44bUJOWElDelRGMHd3Tmc?oc=5","date":"2025-05-07","type":"pipeline","source":"Oncology News Central","summary":"Cannabis in Community Cancer Care: Where Do Things Stand? - Oncology News Central","headline":"Cannabis in Community Cancer Care: Where Do Things Stand?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQkFVTTQ1Ym5kdklESHhfRGRYSVg4eGhCaFc3MV8zSkFhcjRkUFBiWlV4MzMxaDlYcTNva3RqVVJ1Q3JfNWFiM1dCMl9wRnVwQ0xISmN4SURHVFJjZHl0RHZzQjJaMnh4WS1jZ29ITW4xX0gxZjNtNFZ2andERWU1U3Bxd3RXNzVVLUMzVmtxLTk3WWhfZWxDbDUzaTFFRTlCTHgwLXlab0ZCd2tPTW9VUjhzT1RRaEFK?oc=5","date":"2025-05-06","type":"pipeline","source":"Oncology News Central","summary":"Practice-Ending Event? Community Oncology Braces for Drug Pricing Fallout - Oncology News Central","headline":"Practice-Ending Event? Community Oncology Braces for Drug Pricing Fallout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOaXYwb08wTjdOeEpzMDg4UlVhdlNiY1dkTXdwcU1OSk9kV3V3WXUtaGt0WHRucl94OUFZdFh2X2liY01uLUZjbkNKN1MwbFF5ckh4TktFR3ZkNXpkeVBwelVEQ0RTQzJMckZlWkV1TDNpMjI0RUxIZFdiZGt6M25TQ0UyNzRwajk4d2NZT2ZhVTJ2V01uVjhBVFhjSHhFUVBYTXN1eEtXQQ?oc=5","date":"2025-05-02","type":"pipeline","source":"Pharmacy Times","summary":"Community Oncology Faces Crossroads Under the Inflation Reduction Act - Pharmacy Times","headline":"Community Oncology Faces Crossroads Under the Inflation Reduction Act","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9vMnQ3V3VibDdTMVlhMjVjaEpJT21zaG5wM3FscUtvTElXOVdUM0c3TjlqaUl2UU5yV1IwcHFDb1Z3N1U0RFhDbDNjT0hzSUU5bW1WNktMX1l0aGM3ZGloUUpKWlVHR0E1czFYVDlmbngzVzV4d3ZhMEVB?oc=5","date":"2025-01-16","type":"pipeline","source":"The New York Times","summary":"How a Company Makes Millions Off a Hospital Program Meant to Help the Poor (Published 2025) - The New York Times","headline":"How a Company Makes Millions Off a Hospital Program Meant to Help the Poor (Published 2025)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5EY1VkWE1EODd3cFVWVFQ0STA2aEtqNEJRbTVaZW1qdTJjVUlUZjY0ZV9tV1pZZDhjaWVJTktFaDNydS1nbjctLTlzWDNkYkZyQTJ2YmpGMXJ3bC1nTlIteUNab2JZVFo3QmV2bVhRdVI3aGM?oc=5","date":"2024-09-26","type":"pipeline","source":"Taylor & Francis Online","summary":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online","headline":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOWGpWd21zSWFCY3diSlRWY29xdkZZR2VxdnZHRDYwVFM2dElVa2gtelR4TFUwVm1KdXZaQ191VW1MZkJOdERJOWlMaEdvSEc2YXdYelJnZXBCYXJ3S3B6bnh4TjlZTGgxeTZmUkZaVml5NElTSDdqa0RmNVVqVHNaWFR5ZndfLTBxb3NnM2M2WWpIRE1VdmpQSg?oc=5","date":"2024-06-19","type":"pipeline","source":"Clinical Leader","summary":"New Law Expected To Boost Clinical Research In Brazil - Clinical Leader","headline":"New Law Expected To Boost Clinical Research In Brazil","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxNUV9qV1FBSVJ1eFBwR0Noc0xXTndac3BEZmR5bkYzOUxmY0xza1ZpSGFNWDZrQmY2TzY1Vk1Jclh5RXY4RGdLck9adjUzWlNKalVPZXZBSlFDU3NudVRBc3dSN3c2TkVUcFFpVlNFa3p4MEw2WnlFNDNTcnJtazJ5UzkxdzNZYUZfOF9RbWtWRHBwSTFILXhyMXA3dkM0Vll3T1NTM3ZFYkJ3MEpOeEM0SWpnMTV0Tm1MN19UdVFIZlhnbk43RnVVWGtNYnRDUzlVakNPa2QzdVdYUjBlQXUxalYtcXE4bkpZdnIwNThXUUdqdUlRSDFTTHZwQWhSUXY2RS1YVm5XVVBtOFJHbGFvTEV6WXVFNkpXRW02a1NTYVY0OW1uYmkySTdleTliOTYzbTZ3Wi12TzBOV3lrVFJfLUJWV3lRU2ItcHZjZGNnX01EaF8t?oc=5","date":"2022-03-29","type":"pipeline","source":"prnewswire.com","summary":"Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment - prnewswire.com","headline":"Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Addr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZzlIVlVGb1h6NXl5aDlIRlFfdXdsQW5Ycmh6Z3VNelM5YUZRaVRBUUllSjdoS3dnZWhyc29vMlJlMlgtdHhncGktM0dhTm9qNXlEdDljbkRlWXB2Ymx5RlBkbVdoaS03aUVfY3RIVnZJS3lIb0xmclBNaEpQMlNpcXR5WERpdXdNOWtEbXRvRVpwODRHQnpwcQ?oc=5","date":"2021-11-02","type":"trial","source":"VA News and Information (.gov)","summary":"VA joins alliance to boost access to ‘decentralized’ clinical trials - VA News and Information (.gov)","headline":"VA joins alliance to boost access to ‘decentralized’ clinical trials - VA News and Information (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNSGNVRnNmMmF3U3RBcjhaTEFxOFVTRTdzRktzeWFJRmxPMEVSaVlZNW0yYmVPd25CWGhnUGxHQmczMjRWNTZaaEYyVktNLTV1bVJyY3RVbG5FakJmX0s2SFBMb3ZsM3hpdTRXR3h2c3BMcmRBeUx1ZGtwREt6RVBWZGZtN01pbEhnRFRyNnR6UFE3NzZoeE1kXzViTHR2V3B6cmVqNVNySXVrTnJsd2F4YmYya3ZtdW55ek9pLWtfZy04SzB4M1kzNlVKRVlTUlN5OTM1cjBtVUlselFEYWNuQWpRSFg4TGxwMjhoY1NsNk9xM05Rb2RtdW5zWjRSTjROR1VBS0t2UVc?oc=5","date":"2020-09-10","type":"trial","source":"ascopost.com","summary":"SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough? - ascopost.com","headline":"SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOaWVHWnFWMl9JRnl5YkhFWEQwdzNndUs5ZzFhWDFfcExSdWdOSWlYN3hxd3FpSDdwcjV2MlF3LU5GLWhvTkh0eTVHeERZS0kxQXVtaTVJdU4taWpxMU9ZeTBYc2ZTUUw2dzJBQy1vb2pVSGhHMm5QWWlNTzNkTFMzQmYxRHRnQ0M2NGg1cGFKbktfTzd5M0tEWXVGM21GUGdUMElGS1N2ZVJmRlNCbmZuRlpvUjRBSzd2SmxDaF95cGhKeGc?oc=5","date":"2019-07-23","type":"trial","source":"Inside Precision Medicine","summary":"Syapse, Pfizer Ink Real-World Data Precision Oncology Collaboration - Inside Precision Medicine","headline":"Syapse, Pfizer Ink Real-World Data Precision Oncology Collaboration","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":1,"phase_2":2,"discontinued":1,"phase_1":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}